To overcome this critical limitation, the next generation of COVID-19 vaccines should also target other highly conserved structural and non-structural SARS-CoV-2 antigens capable of inducing protection by cross-reactive CD4+ and CD8+ T cells (1, 106). This evidence concerns the gene CD8A and COVID-19.